Stability of Plasmid DNA Products: A Review of the Data For any pharmaceutical product, an important consideration is the handling and environmental conditions that the material may experience from the time it is manufactured until final dosing of a patient. Plasmid DNA is generally recognized to have exceptional stability compared to other biologics such as… Read More »
GeneOne Life Science Receives Approval of IND by the Korean Ministry of Food and Drug Safety (KMFDS) of MERS-CoV Plasmid DNA vaccine, GLS-5300, for a Phase I/IIa Clinical Trial in Korea SEOUL, KOREA (PRWEB) September 17, 2017 GeneOne Life Science, Inc. announces that it has received approval from the South Korean Ministry of Food and Drug… Read More »
VGXI has reopened and we are getting back to normal operations. Our thoughts are with all those who have been affected by Hurricane Harvey, including our employees, their families, and all our neighbors in the area. For any who would like to contribute to the recovery effort, please consider a donation to one of the… Read More »
Update: VGXI will open for business on Thursday, August 31, 2017. To ensure the safety of our employees and their families, VGXI closed from Monday through Wednesday, August 28th – 30th, 2017. Please stay safe and check back on our website or facebook page for updates.
Heading to Paris in October? Meet with representatives from VGXI and learn more about our products and services! We also welcome requests for partnering meetings during the conference. Contact Us today to make arrangements. 2017 International Society of Vaccines Annual Congress October 5 – 7, 2017 Institute Pasteur Paris, France
Did you miss us at ASGCT? Download our poster at the link below: Novel Method for RNA Quantification and Exclusion from Plasmid DNA Vector Purification Process Stream Presented on Thursday, May 11, 2017 from 5:15 pm – 7:15 pm Session Information: Vector and Cell Engineering and Manufacturing Location: Exhibit Hall C & B South Abstract #484… Read More »
VGXI announced that on April 10th, 2017 the corporation won the award for Best Production / Process Development at the 10th Annual ViE Awards Ceremony held at the 2017 World Vaccine Congress in Washington, D.C.
Votes are still being accepted for the shortlist of companies in each category! Show your support for VGXI by supporting us in the category of “Best Contract Manufacturing Organization” AND “Best Production/Process Development” for the Vaccine Industry Excellence Awards. Winners will be announced at the World Vaccine Congress in Washington DC in April, 2017. Follow this link to… Read More »
On November 18, 2016 VGXI hosted a roundtable discussion with US Congressman Pete Olson and key biotech industry leaders. From left: U.S. Congressman Pete Olson; Ann Tanabe, CEO of BioHouston; Young Park, CEO of GeneOne Life Science; Jim Greenwood, President of BIO; Dorothy Peterson, VP of Operations at VGXI; and Tom Kowalski, President and CEO… Read More »
SEOUL, KOREA (PRWEB) JULY 26, 2016 GeneOne Life Science, Inc. (“GeneOne” KOSPI: 011000) today announced the dosing of the first subjects in its multi-center Phase I trial to evaluate the Zika DNA vaccine (GLS-5700). Refer to ClinicalTrials.Gov, study number NCT02809443. GeneOne has received approval from both the US FDA and Health Canada’s Health Products and… Read More »
On July 13th, 2016 VGXI was featured on KPRC Channel 2 News for their role in manufacturing the first Zika DNA Vaccine approved by the FDA for testing in human clinical trials. Follow this this link or click below to read the full story and watch the video: For more information, contact: Christy Franco, PhD… Read More »
U.S. Congressman Kevin Brady visits VGXI to celebrate the grand opening for their new small scale cGMP manufacturing facility, located in The Woodlands, TX. VGXI Ribbon Cutting, from left: J.J. Hollie, President and CEO of The Woodlands Chamber of Commerce; U.S. Congressman Kevin Brady; Young Park, CEO of GeneOne Life Science; Dorothy Peterson, VP of… Read More »